Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive dengue vaccine rollout under the microscope: 800,000 recipients analyzed

NCT ID NCT07501793

Knowledge-focused Sponsor: Tam Anh Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviews the records of up to 800,000 people who received the TAK-003 (Qdenga) dengue vaccine at VNVC centers in Vietnam between September 2024 and September 2025. Researchers will look at age, sex, location, and vaccination history to see who got the vaccine and how. No new tests or contact with participants is involved—only existing data is used.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TAK-003 (Qdenga) dengue vaccine
What this could lead to
If successful, this study could help public health officials understand who is getting the dengue vaccine and how to improve vaccination campaigns in Vietnam.
What could go wrong
This is an observational study using existing records, so it cannot prove the vaccine's effectiveness or safety. It only describes who got vaccinated, not why or what happened afterward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All individuals who were vaccinated with at least one dose of TAK-003 at all VNVC vaccination centers in Vietnam from 26/09/2024 to 30/09/2025

Ages

4 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All individuals who were vaccinated with at least one dose of TAK-003 at all VNVC vaccination centers in Vietnam from 26/09/2024 to 30/09/2025 Exclusion Criteria: * Cases in which TAK-003 vaccination occurred outside the defined study period (from September 26, 2024, to September 30, 2025). * Records that are duplicates, missing or contain inconsistent information on key demographic or clinical characteristics (age, sex, TAK-003 dose \[first or second\]) as such data are essential for analysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for All individuals who have received at least one dose of tak-003 (qdenga) dengue vaccine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dengue disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

All individuals who have received at least one dose of tak-003 (qdenga) dengue vaccine Dengue

Contacts and locations

Locations

  • Vietnam Vaccine Joint Stock Company

    Ho Chi Minh City, Ho Chi Minh, 700000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.